JSC Vector-BiAlgam (based in the Novosibirsk region) has put off the launch of its second facility for filling ampoules and insulin vials with an annual capacity of 20 million doses until the end of December 2019.
“An automated filling system with capabilities to fill ampoules and insulin vials is expected to arrive from Italy in October. It is likely to be commissioned in December 2019, or in January 2020,”
the company’s general director, Leonid Nikulin, told Interfax.
The system’s launch was earlier scheduled for November 2019.
Investment in the launch will amount to 300 million rubles and will be partially drawn in bank loans. A subsidy amounting to about 50 million rubles will be provided from the region budget, he said.
“The company’s own pharmaceutical products and contract drugs will be used, he also said. Talks are underway to introduce other pharmaceutical products. The production line’s annual capacity is 10 million ampoules and 10 million vials,”
It will be the second production facility of its kind under the current reconstruction program. Vector-BiAlgam launched the first automated system for filling hepatitis-A vaccine into syringes at the beginning of 2019. Investment in the project amounted to 365 million rubles.
JSC Vector-BiAlgam was established on the basis of the state virology and bioengineering research center Vector. The company is wholly owned by Nikulin. Its revenue amounted to 556.9 million rubles and net profit 175.5 million rubles in 2017, according to the SPARK-Interfax database.